百特醫療 (BAX) 2013 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's first-quarter earnings conference call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)第一季財報電話會議。在今天電話會議的問答環節開始前,您的線路將維持僅收聽模式。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, this call is being recorded by Baxter, and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    提醒各位,本次電話會議由百特錄音,並屬受著作權保護之資料。未經百特許可,不得錄音或轉播。如您有任何異議,請於此時中斷連線。

  • I would now like to turn the call over to Ms. Mary Kay Ladone, Corporate Vice President, Investor Relations at Baxter International. Ms. Ladone, you may begin.

    現在我想把電話會議交給百特國際企業副總裁暨投資人關係負責人 Mary Kay Ladone 女士。Ladone 女士,請開始。

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Thanks, John. Good morning, everyone, and welcome to our Q1 2013 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International, and Bob Hombach, Chief Financial Officer.

    謝謝你,John。各位早安,歡迎參加我們 2013 年第一季(Q1 2013)財報電話會議。今天與我一同出席的有百特國際執行長兼董事長 Bob Parkinson,以及財務長 Bob Hombach。

  • Before we get started, let me remind you that this presentation, including comments regarding our financial outlook, new product developments and regulatory matters, contain forward-looking statements that involve risks and uncertainties, and of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.

    在開始之前,先提醒各位,本簡報(包括關於我們財務展望、新產品開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期有重大差異之因素的更多細節,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件。

  • In addition, in today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已收錄於我們今早發布並可於官網取得的財報新聞稿中。

  • Now, I would like to turn the call over to Bob Parkinson.

    現在,我想把電話會議交給 Bob Parkinson。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Thanks, Mary Kay. Good morning, everybody; thank you for calling in. As you saw in the press release that was issued earlier this morning, Baxter's first-quarter financial results were in line with our expectations, and we've also confirmed guidance for the full year for 2013. In the first quarter, adjusted earnings per diluted share increased 4% to $1.05 per diluted share, and worldwide sales increased 2%. And our financial outlook for the full year includes sales growth of approximately 10%, which reflects the impact of the Gambro acquisition, and adjusted earnings per diluted share of $4.60 to $4.70.

    謝謝你,Mary Kay。各位早安;感謝各位來電參與。如各位今早稍早發布的新聞稿所見,百特第一季財務結果符合我們的預期,我們也確認了 2013 全年的財測指引。第一季,調整後稀釋每股盈餘成長 4%,至每股稀釋後 1.05 美元;全球銷售額成長 2%。我們對全年財務展望包括:銷售成長約 10%(反映 Gambro 併購的影響),以及調整後稀釋每股盈餘 4.60 至 4.70 美元。

  • Even in the face of a very challenging macroenvironment, Baxter continued to make investments to support geographic expansion initiatives and new product introductions, while advancing a number of programs that improve the quality of care, and address key high-potential areas of unmet medical need. A few recent achievements include the advancement of our home hemodialysis device, VIVIA. As you know, last year we completed the first clinical trial in the US, evaluating the performance and safety of this new device, and we've initiated a second in-center nocturnal hemodialysis trial in Canada. We remain on track to complete this trial in the second quarter, which will be used to support CE Marking in Europe later this year.

    即使面對極具挑戰的總體環境,百特仍持續投資以支持地理擴張計畫與新產品導入,同時推進多項可提升照護品質的方案,並聚焦於若干具高潛力、尚未被滿足的醫療需求領域。近期幾項成果包括我們家用血液透析裝置 VIVIA 的研發進展。如各位所知,去年我們在美國完成第一項臨床試驗,評估此新裝置的效能與安全性,並已在加拿大啟動第二項院內夜間血液透析試驗。我們仍按計畫於第二季完成該試驗,並將用以支持今年稍晚在歐洲取得 CE 認證。

  • Within our leading hemophilia franchise, we've achieved a number of milestones, including the initiation of a global Phase III clinical trial of BAX817, a recombinant factor VIIa therapy for hemophilia A patients with inhibitors. And we also announced results from a pivotal Phase III study evaluating routine prophylaxis of FEIBA compared to on-demand treatment in patients with hemophilia A or B, and inhibitors. The presence of an inhibitor, as you know, makes response to treatment more challenging, and patients with inhibitors have an increased risk of developing complications such as joint damage. Topline results from the study showed a 72.5% reduction in the median annual bleed rate with prophylaxis treatment. This Phase III study supported the filing of a biologics license application with the FDA during the first quarter, and earlier this week Baxter was granted orphan drug designation for the prophylaxis indication.

    在我們領先的血友病產品線中,我們達成多項里程碑,包括啟動 BAX817 的全球第三期臨床試驗;BAX817 為重組第 VIIa 因子療法,適用於具有抑制抗體的 A 型血友病患者。我們也公布一項關鍵第三期研究結果,該研究評估 FEIBA 的常規預防性治療,相較於在 A 型或 B 型血友病且具有抑制抗體患者中的按需治療。如各位所知,抑制抗體的存在使治療反應更具挑戰,且具有抑制抗體的患者發生關節損傷等併發症的風險更高。研究的主要結果顯示,採用預防性治療可使年出血率中位數降低 72.5%。此第三期研究支持我們於第一季向 FDA 提交生物製劑許可申請(BLA),且本週稍早百特亦獲核准針對該預防性適應症取得孤兒藥資格認定。

  • Also within the hemophilia franchise, Baxter began dosing the first patients in the Phase III trial of BAX855, a longer-acting PEGylated factor VIII therapy based on the full-length ADVATE molecule with an increased half-life. With efficacy and safety as the primary goals for selecting a therapy, BAX855 retains the underlying attributes of ADVATE, potentially offering alternative treatment regimen resulting in fewer infusions.

    同樣在血友病產品線方面,百特已開始在 BAX855 的第三期試驗中對首批患者給藥;BAX855 為長效型 PEG 化第 VIII 因子療法,以全長 ADVATE 分子為基礎並延長半衰期。在以療效與安全性作為選擇治療的主要目標下,BAX855 保留 ADVATE 的核心特性,並可能提供替代性的治療方案,進而減少輸注次數。

  • In the biotherapeutics franchise, Baxter and our partner, Halozyme Therapeutics, announced a positive opinion in Europe for the use of HyQvia as a replacement therapy for adult patients with primary and secondary immunodeficiencies. HyQvia is a combination of human normal immunoglobulin and recombinant human hyaluronidase, which facilitates the dispersion and absorption of the therapy. Upon receiving Marking authorization from the European Commission, Baxter plans to launch HyQvia in select European markets later this year.

    在生物治療產品線方面,百特與合作夥伴 Halozyme Therapeutics 宣布,HyQvia 在歐洲獲得正面意見,可用作成人原發性與續發性免疫缺陷患者的替代治療。HyQvia 為人類正常免疫球蛋白與重組人類透明質酸酶的組合,可促進療法的分散與吸收。在取得歐盟執委會的上市許可(Marking authorization)後,百特計畫於今年稍晚在部分歐洲市場推出 HyQvia。

  • We also continued to advance development of GAMMAGARD LIQUID as a possible treatment for Alzheimer's disease. As you know, we completed the first Phase III study for Alzheimer's in December, recently locked the database, and expect to release topline results during the second quarter. A second Phase III trial was initiated in the first quarter of 2012, and we have now randomized more than 200 of the estimated 400 patients, and we expect to complete this study in 2015.

    我們也持續推進 GAMMAGARD LIQUID 作為阿茲海默症可能治療方案的開發。如各位所知,我們已於 12 月完成第一項阿茲海默症第三期研究,近期已完成資料庫鎖定,並預期於第二季公布主要結果。第二項第三期試驗於 2012 年第一季啟動;目前我們已完成超過 200 名(預計約 400 名)患者的隨機分派,並預期於 2015 年完成該研究。

  • On the business development front, we acquired the investigational hemophilia compound OBI-1 from Inspiration Biopharmaceuticals, and related assets, including manufacturing operations from Ipsen Pharma. OBI-1 is a recombinant porcine factor VIII currently in Phase III clinical studies for the treatment of bleeding in people with acquired hemophilia, a rare, potentially life-threatening bleeding disorder, which, unlike congenital hemophilia, typically affects older adults, and occurs equally in both males and females. OBI-1 received orphan drug designation in the United States and Europe, and was recently granted fast-track designation by the FDA for this indication. OBI-1 has the potential to address existing unmet needs for hemophilia patients, and over time, represents a $200-million opportunity for the Company.

    在業務開發方面,我們自 Inspiration Biopharmaceuticals 收購了研發中血友病化合物 OBI-1 及相關資產,並自 Ipsen Pharma 取得包含製造營運在內的相關資產。OBI-1 為重組豬源第 VIII 因子,目前正進行第三期臨床研究,用於治療後天性血友病患者的出血;後天性血友病是一種罕見且可能危及生命的出血性疾病,與先天性血友病不同,通常影響年長成人,且男女發生率相當。OBI-1 已在美國與歐洲取得孤兒藥資格認定,且近期亦獲 FDA 就此適應症授予快速通道(fast-track)資格。OBI-1 有潛力滿足血友病患者現有未被滿足的需求,並在時間推進下,為公司帶來 2 億美元的機會。

  • And finally, we received US regulatory clearance for our proposed acquisition of Gambro AB, a global innovator in hemodialysis and acute renal technologies. This acquisition enhances Baxter's competitive position by creating a global renal therapies business with a comprehensive product offering for both chronic and acute dialysis patients. And positions the Company to capitalize on the significant opportunity presented by the large and growing global dialysis products market. Pending additional regulatory approvals, we continue to expect the transaction to close at the end of the second quarter.

    最後,我們已取得美國監管機關對我們擬收購 Gambro AB 的核准;Gambro AB 為血液透析與急性腎臟技術領域的全球創新者。此收購將透過打造具完整產品組合、同時服務慢性與急性透析患者的全球腎臟治療事業,強化百特的競爭地位。並使公司得以掌握全球透析產品市場龐大且持續成長所帶來的重大機會。在仍待取得其他監管核准的前提下,我們仍預期交易將於第二季末完成交割。

  • In closing, Baxter's portfolio remains strong, and we continue to benefit from our focus on life-saving therapies. In 2013 and beyond, we will focus on the four growth factors that support our strategic objectives, and enable us to serve the interest of patients, providers, and other key stakeholders. These four factors include -- enhancing growth by optimizing our core business portfolio; advancing the Company's new product pipeline; capitalizing on the opportunity to develop new product models, which include public and private partnerships; and pursuing business development initiatives that deliver enhanced returns in the near and long term. With this in mind, Baxter will fulfill our mission of improving quality and access to care, as we save and sustain lives globally. And as always, I'd be happy to address any questions that you might have on these or other topics during the Q&A.

    總結而言,百特的產品組合依然強勁,我們也持續受益於對挽救生命療法的專注。在 2013 年及未來,我們將聚焦於四項支持策略目標的成長因素,使我們能服務患者、醫療提供者及其他關鍵利害關係人的利益。這四項因素包括——透過最佳化核心業務產品組合以提升成長;推進公司的新產品研發管線;把握開發新產品模式的機會(包括公私部門合作夥伴關係);以及推動可在短期與長期帶來更佳報酬的業務開發計畫。基於此,百特將履行我們提升照護品質與可近性的使命,並在全球挽救與延續生命。一如往常,我也很樂意在問答環節就上述或其他主題回答各位可能提出的任何問題。

  • So, with that, I would like to ask Bob to review our financial results for the quarter and also guidance for 2013. Bob?

    那麼,基於以上,我想請 Bob 回顧我們本季的財務結果,以及 2013 年的展望指引。Bob?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Thanks, Bob, and good morning, everyone. As Bob mentioned, earnings per diluted share in the first quarter, excluding special items, increased 4% to $1.05 per diluted share, which was at the higher end of our guidance range of $1.03 to $1.05 per diluted share. As we've mentioned in the press release, GAAP results include after-tax special items of $29 million, or $0.05 per diluted share. The special items in the quarter were primarily associated with deal-related costs for the planned acquisition of Gambro AB.

    謝謝,Bob,各位早安。如 Bob 所提到,第一季在排除特殊項目後,每股稀釋盈餘較去年同期成長 4%,至每股稀釋盈餘 1.05 美元,位於我們每股稀釋盈餘 1.03 至 1.05 美元指引區間的高端。如我們在新聞稿中所提到,GAAP 結果包含稅後特殊項目 2,900 萬美元,或每股稀釋盈餘 0.05 美元。本季的特殊項目主要與計畫收購 Gambro AB 的交易相關成本有關。

  • Now, let me briefly walk you through the P&L by line item for the quarter, before turning to our financial outlook for full-year 2013. Starting with sales -- worldwide sales of more than $3.4 billion in the first quarter increased 2% on both a reported and constant-currency basis. Growth was driven primarily by acceleration in emerging markets, particularly BRIC countries, and solid performance in several key franchises within BioScience, which offset softness in the US Medical Products business.

    接下來,在談到我們 2013 年全年財務展望之前,我先按損益表各項目簡要帶各位走過本季表現。先從營收開始——第一季全球銷售額超過 34 億美元,按報告基礎與固定匯率基礎均成長 2%。成長主要由新興市場(尤其是 BRIC 國家)的加速成長,以及 BioScience 內數個關鍵產品線的穩健表現所帶動,抵銷了美國醫療產品業務的疲弱。

  • In terms of individual business performance, global BioScience sales of $1.5 billion advanced 5% on both a reported and constant-currency basis in the first quarter. Within the product categories, hemophilia sales of $765 million increased 3% on both a reported and constant-currency basis. US sales growth was strong, as sales advanced 7%, driven by double-digit growth of ADVATE and FEIBA. This more than offset the impact of European austerity measures and international tenders. We continue to be pleased with the benefits associated with our differentiated label of ADVATE, as we continue to drive conversion from plasma-derived therapies and competitive offerings, and enhanced penetration of prophylactic treatment.

    就各業務的個別表現而言,第一季全球 BioScience 銷售額為 15 億美元,按報告基礎與固定匯率基礎均成長 5%。在產品類別中,血友病產品銷售額為 7.65 億美元,按報告基礎與固定匯率基礎均成長 3%。美國銷售成長強勁,銷售額成長 7%,主要由 ADVATE 與 FEIBA 的兩位數成長所帶動。這已足以抵銷歐洲緊縮措施與國際標案的影響。我們持續對 ADVATE 差異化標籤所帶來的效益感到滿意,因為我們持續推動由血漿衍生療法與競品的轉換,並提升預防性治療的滲透率。

  • In biotherapeutics, sales of $509 million increased 2% on both a reported and constant-currency basis. As expected, sales growth of GAMMAGARD LIQUID and Albumin was in low-single digits, driven primarily by improved pricing as we remain capacity-constrained, while sales of alpha-1 treatments continued strong growth.

    在生物治療(biotherapeutics)方面,銷售額 5.09 億美元,按報告基礎與固定匯率基礎均成長 2%。如預期,GAMMAGARD LIQUID 與白蛋白(Albumin)的銷售成長為低個位數,主要由於在產能仍受限的情況下,價格改善所帶動;同時,alpha-1 治療產品的銷售持續強勁成長。

  • In the first quarter, sales in BioSurgery of $172 million increased 12%. After adjusting for foreign currency, sales rose 11%, driven by growth of TISSEEL and a benefit from the Synovis acquisition of approximately $10 million.

    第一季 BioSurgery 銷售額為 1.72 億美元,成長 12%。若調整匯率因素,銷售成長 11%,主要由 TISSEEL 的成長所帶動,並受惠於 Synovis 收購案約 1,000 萬美元的貢獻。

  • Finally, vaccine revenues totaled $84 million in the quarter, and increased 25%. Excluding foreign currency, sales increased 28%, driven primarily by strong demand for the FSME vaccine, and incremental milestone payments totaling approximately $10 million related to our ongoing collaborations on the development of influenza vaccines.

    最後,本季疫苗營收合計 8,400 萬美元,成長 25%。排除匯率因素後,銷售成長 28%,主要由 FSME 疫苗的強勁需求所帶動,並包含與我們持續合作開發流感疫苗相關、合計約 1,000 萬美元的新增里程碑款項。

  • In Medical Products, global sales in the first quarter exceeded $1.9 billion, and were comparable to the prior year. Excluding foreign currency, sales declined 1%. Within the product categories, renal sales totaled $590 million, and were flat to the prior year, while on a constant-currency basis, sales were up 1%. Sales in this category were impacted by austerity measures implemented in China, the timing of tenders, and lower HD sales, which offset the contribution from patient gains in the US and emerging markets.

    在醫療產品(Medical Products)方面,第一季全球銷售額超過 19 億美元,與去年同期大致持平。排除匯率因素後,銷售下滑 1%。在產品類別中,腎臟相關產品銷售額合計 5.90 億美元,與去年同期持平;以固定匯率計,銷售成長 1%。該類別銷售受到中國實施的緊縮措施、標案時點,以及血液透析(HD)銷售較低的影響,抵銷了美國與新興市場病患數增加所帶來的貢獻。

  • Sales in the fluid systems category of $740 million increased 3%, and on a constant-currency basis, sales increased 2%. Performance continues to be driven by solid demand for IV solutions and price improvements for certain injectable drugs like cyclophosphamide, which collectively offset lower sales of infusion pumps and access sets as planned. Specialty pharmaceuticals, which includes our inhaled anesthetics and nutritional therapies, posted sales of $363 million, reflecting a decline of 1% on a reported basis, and a 2% decline on a constant-currency basis. Double-digit growth of anesthetics across international markets was driven by increased penetration in new markets, which was more than offset by lower sales in the US attributed to softness in surgical procedures and fluctuations in the purchasing patterns of US wholesalers.

    輸液系統(fluid systems)類別銷售額為 7.40 億美元,成長 3%;以固定匯率計,銷售成長 2%。表現持續由靜脈注射(IV)溶液的穩健需求,以及特定注射用藥(如 cyclophosphamide,環磷醯胺)的價格改善所帶動,合計抵銷了如計畫所預期的輸液幫浦與輸液通路組(access sets)銷售下滑。專科藥品(specialty pharmaceuticals,包含我們的吸入式麻醉劑與營養治療)銷售額為 3.63 億美元,按報告基礎下滑 1%,以固定匯率計下滑 2%。國際市場麻醉劑的兩位數成長,主要由新市場滲透率提升所帶動,但被美國銷售下滑所抵銷;美國下滑歸因於手術量疲弱,以及美國批發商採購模式的波動。

  • Finally, sales in biopharma solutions, which is our pharma partnering business, totaled $225 million, representing a 10% decline on a reported basis, and 11% decline on a constant-currency basis. This was due to temporary constraints, which resulted in delayed shipments to customers, which have been resolved, and shipments have resumed.

    最後,生物製藥解決方案(biopharma solutions,即我們的製藥合作夥伴業務)銷售額合計 2.25 億美元,按報告基礎下滑 10%,以固定匯率計下滑 11%。原因在於短期產能限制導致對客戶的出貨延遲;該問題已解決,出貨已恢復。

  • Turning to the rest of the P&L -- gross margin in the quarter of 51% reflects margin expansion of 20 basis points versus the prior-year margin of 50.8%. This was the result of underlying operational expansion driven primarily by the benefit of positive mix, which offset a number of headwinds, including incremental pension expense, the Medical Device Tax, government austerity measures, and approximately $20 million of accelerated costs.

    接著看損益表其餘項目——本季毛利率為 51%,較去年同期 50.8% 擴張 20 個基點。這主要來自營運面的內生性改善,主要受惠於有利的產品組合,抵銷了多項逆風因素,包括新增的退休金費用、醫療器材稅(Medical Device Tax)、政府緊縮措施,以及約 2,000 萬美元的加速成本。

  • SG&A totaled $778 million, and increased 5%, driven by the impact of incremental pension expense, investments we are making in promotional and marketing initiatives, and within international markets to enhance our global presence. In total, these items more than offset a benefit from tight management of discretionary spending and operational efficiencies derived from our process reengineering efforts. R&D spending in the quarter increased 4%, and totaled $246 million, reflecting the progress we're making in advancing a number of programs in our pipeline, including those in our leading hemophilia franchise, Alzheimer's, and other key programs.

    銷售、一般及行政費用(SG&A)合計 7.78 億美元,成長 5%,主要受新增退休金費用影響,並反映我們在推廣與行銷計畫上的投資,以及在國際市場強化全球布局的投入。整體而言,這些項目已超過因嚴格管理可自由支配支出,以及流程再造所帶來的營運效率提升所產生的效益。本季研發(R&D)支出成長 4%,合計 2.46 億美元,反映我們在推進多項研發管線計畫上的進展,包括我們領先的血友病產品線、阿茲海默症,以及其他關鍵計畫。

  • The operating margin in the quarter was 21.3%. Interest expense was $25 million compared to $18 million last year. This increase is due to incremental expense associated with the debt issuance last year, and lower interest income. Other income totaled $30 million in the quarter, and is primarily attributable to the favorable foreign-exchange impact on balance sheet positions, and a gain of $10 million associated with the sale of intangible assets. The tax rate was 21.3% for the quarter, in line with expectations, and includes a modest benefit from the 2012 R&D tax credit. And as previously mentioned, adjusted earnings per diluted share of $1.05 increased 4%.

    本季營業利益率為 21.3%。利息費用為 2,500 萬美元,去年同期為 1,800 萬美元。此增幅主要由去年發債所帶來的新增費用,以及利息收入較低所致。本季其他收益合計 3,000 萬美元,主要歸因於外匯對資產負債表部位的有利影響,以及出售無形資產所帶來的 1,000 萬美元收益。本季有效稅率為 21.3%,符合預期,並包含 2012 年研發稅額抵減帶來的小幅利益。如先前所述,調整後每股稀釋盈餘 1.05 美元成長 4%。

  • Turning to cash flow -- cash flow from operations in the first quarter totaled $386 million, and capital expenditures totaled $292 million, both in line with our expectations. DSO ended the quarter at 53.6 days, reflecting a 4-day improvement versus the same period last year, due to a significant reduction in DSOs in certain international markets. Inventory turns of 2.2 turns are modestly lower than the first-quarter last year. As you know, we continue to increase inventory levels to support growing demand, particularly for plasma proteins, as we remain on track to benefit from enhanced capacity in the second half of the year. Lastly, in the quarter we repurchased approximately 8 million shares for $534 million, or on a net basis, 4 million shares for $351 million, in line with our full-year objective.

    接著看現金流——第一季營運活動現金流量合計 3.86 億美元,資本支出合計 2.92 億美元,兩者皆符合我們的預期。應收帳款週轉天數(DSO)季末為 53.6 天,較去年同期改善 4 天,主要因部分國際市場的 DSO 顯著下降。存貨週轉率為 2.2 次,較去年第一季略低。如各位所知,我們持續提高存貨水位以支援成長中的需求,特別是血漿蛋白產品;我們仍按計畫在今年下半年受惠於產能提升。最後,本季我們回購約 800 萬股、金額 5.34 億美元;或以淨額計,回購 400 萬股、金額 3.51 億美元,符合我們全年目標。

  • Finally, let me conclude my comments this morning by providing our financial outlook for the full-year 2013. As you saw in the press release, we confirmed guidance, and continue to expect earnings of $4.60 to $4.70 per diluted share. This includes the impact of the Gambro acquisition, which is projected to close at the end of the second quarter with estimated dilution of $0.10 to $0.15 per diluted share. This dilution is primarily related to non-cash amortization of intangible assets, which will be finalized upon closing.

    最後,讓我在今天上午以提供我們對2013年全年之財務展望來作結。如同您在新聞稿中所見,我們確認了先前的財測指引,並持續預期每股稀釋後盈餘為4.60至4.70美元。此預期包含Gambro收購案的影響;該交易預計於第二季末完成,估計將造成每股稀釋後盈餘稀釋0.10至0.15美元。此稀釋主要與無現金的無形資產攤銷相關,並將於交割完成時最終確定。

  • By line item of the P&L, and starting with sales, we expect sales growth, excluding the impact of foreign currency, of approximately 10%. And this includes a half-year sales contribution from Gambro of approximately $830 million. Excluding Gambro, we continue to expect sales growth on a constant-currency basis of approximately 4%, and at current foreign exchange rates, we expect a modest negative impact on sales for the year.

    就損益表各項目而言,先從營收開始,在排除外幣影響後,我們預期銷售成長約10%。其中包含Gambro約半年的銷售貢獻,約為8.30億美元。若排除Gambro,我們仍預期以固定匯率計算的銷售成長約4%;而以目前匯率水準來看,我們預期外匯對全年銷售將有小幅負面影響。

  • For the full year, given current foreign exchange rates, we now expect gross margin for the Company to be approximately 50.5% for the full year. While year over year we expect margin expansion of approximately 100 basis points in the base Baxter business, this will be more than offset by intangible asset amortization related to Gambro, incremental pension expense, government austerity measures, including the Medical Device Tax, and a negative impact from foreign currency.

    就全年而言,考量目前外匯匯率,我們現在預期公司全年毛利率約為50.5%。雖然我們預期Baxter基礎業務的毛利率年增約100個基點,但這將被與Gambro相關的無形資產攤銷、額外的退休金費用、政府緊縮措施(包括醫療器材稅)、以及外幣的負面影響所抵銷,且抵銷幅度更大。

  • In terms of expense, we expect SG&A to increase approximately 10%, and R&D to grow in mid-single digits, with both line items reflecting leverage in the Baxter expense base along with the addition of Gambro. We continue to expect interest expense to total approximately $170 million, which reflects the impact of the debt issuance associated with the Gambro acquisition. In addition, we now expect Other income to total approximately $10 million for the full year; we expect a tax rate of approximately 22%; and we expect a full-year average share count of approximately 550 million shares, which assumes approximately [$300 million to $400 million] in net share repurchases. From a cash flow perspective, our plan remains to generate cash flow from operations of approximately $3.3 billion, with capital expenditures totaling approximately $1.7 billion, which includes Gambro and the investments we are making to enhance our plasma manufacturing footprint in Covington, Georgia.

    在費用方面,我們預期SG&A約增加10%,研發(R&D)成長約為中個位數百分比;兩者皆反映Baxter費用基礎的槓桿效益,以及併入Gambro的影響。我們仍預期利息費用合計約為1.70億美元,反映與Gambro收購相關的發債影響。此外,我們現在預期全年其他收入合計約為1,000萬美元;預期稅率約22%;並預期全年平均流通股數約5.50億股,假設淨庫藏股回購約為[3.00億至4.00億美元]。就現金流角度而言,我們的計畫仍為營運活動現金流約33億美元,資本支出合計約17億美元,其中包含Gambro,以及我們為強化喬治亞州科溫頓(Covington)血漿製造布局所進行的投資。

  • Let me move to sales, and expand our assumptions for the two businesses and the major product categories. Beginning with Medical Products, on a constant-currency basis, including the half-year contribution related to Gambro, we expect sales growth in the low-teens. Excluding Gambro, we expect sales from Medical Products to grow 3% to 4%. Specifically, we expect Baxter renal sales to grow in low-single digits, which will be augmented by a half-year's sales contribution from Gambro, totaling approximately $830 million.

    接著談銷售,並進一步說明我們對兩大事業與主要產品類別的假設。先從醫療產品(Medical Products)開始,以固定匯率計算並包含Gambro半年的貢獻,我們預期銷售成長為低十位數百分比。若排除Gambro,我們預期醫療產品銷售成長3%至4%。具體而言,我們預期Baxter腎臟相關銷售成長為低個位數百分比,並將由Gambro半年的銷售貢獻所增強,合計約8.30億美元。

  • We continue to expect fluid system sales, which includes IV solutions, infusion pumps, and access sets, to grow in mid-single digits. We expect specialty pharmaceutical sales, which includes our nutritional therapies and inhaled anesthetics, to grow in low-single digits. And we expect our biopharm solutions business to have comparable sales to 2012 of approximately $1 billion.

    我們仍預期輸液系統(fluid system)銷售(包含靜脈輸液(IV)溶液、輸注幫浦與導管組)將以中個位數百分比成長。我們預期特殊藥品(specialty pharmaceutical)銷售(包含營養治療與吸入式麻醉藥)將以低個位數百分比成長。我們也預期生物製藥解決方案(biopharm solutions)業務的銷售將與2012年相當,約為10億美元。

  • For BioScience, we continue to project sales growth, excluding foreign currency, in the 4% to 5% range. Our outlook includes low- to mid-single-digit growth in our hemophilia franchise, which includes recombinant and plasma-derived factor VIII and factor IX therapies, and FEIBA, an inhibitor treatment. We expect mid- to high-single-digit growth in biotherapeutics, driven primarily by strong demand for immunoglobulin therapies, including GAMMAGARD LIQUID and subq therapies, as well as growth in Albumin and our treatments for alpha-1 deficiency.

    在生物科學(BioScience)方面,我們仍預估在排除外幣影響後,銷售成長落在4%至5%區間。我們的展望包含血友病產品線的低至中個位數百分比成長,該產品線包括重組與血漿來源的第VIII因子與第IX因子療法,以及抑制物治療藥物FEIBA。我們預期生物治療(biotherapeutics)將以中至高個位數百分比成長,主要由免疫球蛋白療法(包括GAMMAGARD LIQUID與皮下(subq)療法)的強勁需求所帶動,同時也包含白蛋白(Albumin)以及我們針對α-1缺乏症的治療成長。

  • In BioSurgery, we expect high-single-digit growth. And finally, we expect our vaccine franchise to grow in mid-single digits.

    在生物外科(BioSurgery)方面,我們預期高個位數百分比成長。最後,我們預期疫苗產品線將以中個位數百分比成長。

  • As mentioned in our press release, for the second quarter, we expect earnings per diluted share of $1.12 to $1.14, and sales growth, excluding the impact of foreign currency, of approximately 4%. At current foreign exchange rates, foreign currency may have a modest negative impact on sales growth in the quarter.

    如同我們在新聞稿中提到的,針對第二季,我們預期每股稀釋後盈餘為1.12至1.14美元,且在排除外幣影響後,銷售成長約4%。以目前匯率水準來看,外幣可能對本季銷售成長造成小幅負面影響。

  • Thanks, and now let me open up the call for Q&A.

    謝謝,接下來我開放問答。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • We would like to remind participants of this call is being recorded and a digital replay will be provided on the Baxter website for 30 days at www.baxter.com. David Lewis, Morgan Stanley.

    我們提醒各位與會者,本次電話會議將被錄音,並將於Baxter網站www.baxter.com提供為期30天的數位重播。摩根士丹利(Morgan Stanley)的David Lewis。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Good morning.

    早安。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Morning, David.

    早安,David。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Maybe a couple quick questions on the model and then maybe more of a strategic question. I guess a couple quick nits on the model, at [Specpharm] you talked about a slight change in guidance for the year; I wonder does that reflect more just the utilization environment you are seeing here in the first quarter or any change to what you're thinking about the timing of generics in the back half of the year?

    我想先就模型提兩個快速問題,然後再問一個比較偏策略面的問題。先就模型的幾個小細節,在[Specpharm]方面你提到全年指引有些微調整;我想請問這是否主要反映你們在第一季看到的使用量(utilization)環境,或是你們對今年下半年學名藥上市時點的看法有所改變?

  • And the second financial question was non-op guidance is roughly equivalent to what you guided for a few quarters -- sorry a few months ago, but a very strong non-op quarter this particular quarter, maybe you'd just walk through some of those dynamics. And then one follow-up.

    第二個財務問題是,非營運(non-op)指引大致與你們在幾季——抱歉,是幾個月前——所給的指引相當,但本季非營運表現非常強勁;也許你可以帶我們走一遍其中的一些動態因素。然後我還有一個追問。

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Okay. I think, David, your comments about softer surgical procedures are really what drove it, that there's no change in our expectation about the potential for generic competition later this year in this space, so no change there. And as it relates to the non-op items as I mentioned in my prepared comments, two real drivers there. One, foreign exchange. The other, one sale of an intangible asset, and so the FX item really related to some volatility around the euro in the first quarter. As you know, the euro traded anywhere from up $1.37 to $1.27 during the course of the quarter, and given our balance sheet positions in the quarters and the months in which it was most volatile, we had a pretty significant outcome there. But as I mentioned in my prepared comments, we also took some costs into margin that we hadn't expected for this quarter, we expected later in the year, of approximately $20 million. And so, look at the overall picture, those two kind of offset.

    好的。David,我想你提到的手術量較疲弱,確實是主要驅動因素;我們對今年稍晚此領域可能出現學名藥競爭的預期並沒有改變,所以那部分沒有變。至於非營運項目,如同我在事先準備的發言中提到的,主要有兩個驅動因素。第一是外匯。第二是出售一項無形資產;而外匯項目主要與第一季歐元的波動有關。如你所知,歐元在本季期間交易區間大約從1.37美元到1.27美元不等;考量我們在資產負債表上的部位,以及波動最劇烈的那些季度與月份,我們在那部分出現了相當顯著的結果。但如同我在事先準備的發言中提到的,我們也在毛利中認列了一些本季原本未預期、而是預期在今年稍晚才會發生的成本,約2,000萬美元。因此,從整體來看,這兩項大致互相抵銷。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay. Maybe two strategic questions for Bob, I guess interesting competitive chatter at some recent conferences, Bob, I wonder if you could comment. The first is surrounding Glendale and the progress, there was some discussion that perhaps Baxter is behind in their process at Glendale and the refurbishment. Maybe help us understand where you think you are as it relates to Glendale as it relates to capacity in the back half of the year.

    好的。我想再問Bob兩個策略性問題;Bob,最近在一些會議上有些有趣的競爭面傳聞,我想請你評論一下。第一個是關於Glendale及其進度;有些討論提到Baxter在Glendale的流程與整修(refurbishment)上可能落後。能否幫我們理解一下,就今年下半年產能而言,你認為Glendale目前處於什麼樣的狀態?

  • And then on hemophilia competition, which is obviously coming next year, another strong hemophilia quarter for Baxter this particular quarter. Maybe talk just a little about what you are seeing on the strength of PK dosing and the larger 4,000 unit dose and how you expect that to trend this year? Thank you.

    接著談到血友病的競爭,顯然明年就會到來;而本季對 Baxter 而言又是另一個強勁的血友病季度。能否稍微談談您所看到的 PK 劑量調整的強勁表現,以及較大 4,000 單位劑量的使用情況,並說明您預期今年的趨勢會如何發展?謝謝。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Sure, in terms of old LA we're back in operation, consistent with the timetable that we set up, actually a little bit ahead of schedule. So, we're very pleased with getting that back in production for reasons that we all understand. So no concerns on that issue. Relative to the core hemophilia franchise, we continue to see momentum in the US in response to the PK dosing; prophylaxis use and so on continue to be encouraged by that.

    當然。就舊 LA 而言,我們已恢復運作,符合我們先前設定的時程,實際上還略微提前。因此,我們很高興能讓它恢復生產,原因大家都明白。所以在這個議題上沒有疑慮。至於核心血友病產品線,我們持續看到美國市場因 PK 劑量調整而帶來的動能;預防性治療的使用等也持續受到其帶動。

  • So as it relates to the momentum in that business, particularly in the US and in view of new competitive entrance down the road, fundamentally, David, I would say no change in our position in that regard from what we discussed with you previously, I don't know Mary Kay if you want to add anything to that?

    因此,就該業務的動能而言,特別是在美國,並考量未來將有新的競爭者進入,基本上,David,我會說我們在這方面的立場與先前和你討論的並無改變。我不知道 Mary Kay 你是否要補充?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • No, I was just going to say, David we have started conformance lots in old LA, and as Bob mentioned, we remain on track for clearance and to start shipping product in the third quarter. So no change in expectations there.

    沒有,我只是想說,David,我們已在舊 LA 開始進行符合性批次(conformance lots),如 Bob 所提,我們仍按計畫在第三季取得放行並開始出貨。所以在那方面的預期沒有改變。

  • And I'd also point out that the strong recombinant sales driven really by ADVATE in the US. And we are expecting to take out some inventory as we move throughout the year, so we aren't expecting in our guidance to continue to see as strong performance going forward.

    我也要指出,本季強勁的重組產品銷售主要是由美國的 ADVATE 所帶動。而隨著今年進行,我們預期會去化部分庫存,因此在我們的指引中,並不預期未來仍會持續看到同樣強勁的表現。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay, very helpful, thank you very much.

    好的,非常有幫助,謝謝你們。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Matt Miksic, Piper Jaffray.

    Matt Miksic,Piper Jaffray。

  • Matt Miksic - Analyst

    Matt Miksic - Analyst

  • Thanks. Just a follow-up on hemophilia; you mentioned in your prepared remarks, there was sort of a contribution from competitive gains, there was contribution from increased penetration of prophylaxis, and sort of utilization on the ADVATE side. Could you maybe talk about what kind of share you're starting to see here competitively, how much interest there is and in this sort of flexible dosing model that you have?

    謝謝。就血友病再追問一下;你在事先準備的發言中提到,成長有一部分來自競爭性市占提升,有一部分來自預防性治療滲透率提高,還有一部分來自 ADVATE 端的使用量。你能否談談目前在競爭上你們開始看到怎樣的市占表現,以及市場對你們這種彈性劑量模式的興趣有多大?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • I don't know, Matt, that we can add a lot more to my comments in response to David Lewis's question. We're not going to get into specific market share changes and quote market shares and so on. Again as I said before, we get a good market response, continue to get a good market response to the PK dosing, and prophylaxis use and so on, which we're very encouraged by. It's consistent with what we've expected from the outset, so beyond that I'm not sure that there's a lot more we can say or we want to say at this stage.

    Matt,我不確定我們能在回應 David Lewis 問題時的評論之外再補充太多。我們不會深入談具體的市占變化、引用市占數字等等。如我先前所說,我們對 PK 劑量調整以及預防性治療的使用等,持續獲得良好的市場回饋,這讓我們非常受到鼓舞。這也符合我們一開始的預期,因此除此之外,我不確定此階段我們還能或還想多說什麼。

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • I would just add that the good news here is that we have multiple avenues to drive accelerated growth going forward, converting plasma derived even within our own patient base, converting on-demand to prophylaxis, and then certainly for those patients that are looking for the opportunity to do less infusions on an annual basis moving towards PK dosing. So again we're pursuing all those avenues, and I think the 4,000 IU presentation is going to allow us to continue to drive the PK dosing going forward here. Still somewhat early days because it was the third quarter of last year that we really started launching that, but we're seeing progress on all three fronts.

    我只想補充,好消息是我們有多條途徑可在未來推動加速成長:將血漿來源產品轉換(即使是在我們既有的病患基礎內)、將按需治療轉換為預防性治療,並且對於希望每年減少輸注次數的病患,推動其採用 PK 劑量調整。因此我們正同步推進所有這些途徑,而我認為 4,000 IU 的劑型呈現將使我們能在未來持續推動 PK 劑量調整。目前仍算是早期階段,因為我們真正開始推動是在去年第三季,但我們在這三個面向都看到進展。

  • Matt Miksic - Analyst

    Matt Miksic - Analyst

  • Okay, that's understandable. And on the Alzheimer's program, you mentioned wrapping up the trial in '15, just maybe walk us through if you could, you have made some decent progress. This is the second trial, and about halfway through enrollments currently, can you walk through why it would take, why expected to take until '15 to complete that?

    好的,這可以理解。另外關於阿茲海默症計畫,你提到會在 2015 年完成試驗;能否請你帶我們梳理一下,你們已取得不錯的進展。這是第二個試驗,目前入組大約完成一半;你能否說明為什麼預期要到 2015 年才會完成?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Mary Kay, why don't you handle that?

    Mary Kay,你來回答好嗎?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Sure. Matt, as we mentioned in the prepared comments, we have already enrolled about 200 of the 400 patients, and we are expecting to complete enrollment by the end of this year. As you recall, the trial design for the second Phase III is exactly similar to the first Phase III, so it's an 18-month follow-up, which would mean that we wouldn't complete the trial until mid-2015.

    好的。Matt,如我們在事先準備的評論中提到,我們已入組約 400 名病患中的 200 名,並預期在今年年底前完成入組。如你所記得,第二個第三期試驗的設計與第一個第三期完全相同,因此需要 18 個月的追蹤期,這意味著我們要到 2015 年年中才會完成試驗。

  • Matt Miksic - Analyst

    Matt Miksic - Analyst

  • Great. And then finally just on the fluid systems in the quarter, I didn't catch the color on why exactly the weakness there at least relative to our estimates. It sounded like from your perspective, the growth was in line or sort of solid growth in the quarter but, I guess --

    很好。最後關於本季的輸液系統(fluid systems),我沒有聽清楚為何表現偏弱,至少相對於我們的預估而言。聽起來從你們的角度看,本季成長符合預期或算是穩健成長,但我想——

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Yes, yes it was in line with our expectations, but I think it's important to remember given the pace of activity in 2012 as we finalized the swap out of colleagues and placed a lot of Spectrums in the marketplace. We expected, going into 2013, that pump sales would be lower than 2012, again because of that elevated level of activity, and as we looked at results in the quarter, they were again in line with our expectations, and so no issues there.

    是的,是的,確實符合我們的預期,但我認為重要的是要記得,考量到 2012 年的活動節奏:當時我們完成了同事的替換(swap out),並在市場上投放了大量 Spectrum 設備。因此我們在進入 2013 年時就預期,幫浦銷售會低於 2012 年,原因正是那段期間活動量偏高;而從本季結果來看,也同樣符合我們的預期,所以沒有問題。

  • Matt Miksic - Analyst

    Matt Miksic - Analyst

  • Thanks so much.

    非常感謝。

  • Operator

    Operator

  • Larry Keusch, Raymond James.

    Larry Keusch,Raymond James。

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Can you hear me?

    你們聽得到我嗎?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • We can hear you now Larry, go ahead.

    Larry,我們現在聽得到,請說。

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Thanks, I guess for Bob Hombach, the 2013 guidance when you take the first quarter and the guidance for the 2Q implies that you drive greater EPS in the back half of the year, so could you just remind us again what are the drivers of the increased profitability in the second half of the year?

    謝謝。我想問 Bob Hombach:2013 年的指引,若把第一季表現與第二季指引合併來看,意味著你們在下半年要帶動更高的 EPS;能否再提醒我們,下半年獲利能力提升的驅動因素是什麼?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Sure, sure. Multiple impacts here. So first off, we do expect to have enhanced flexibility on capacity and supply to the market in the plasma business as we move into the third quarter. As we mentioned we are producing now and we expect to be able to start shipping product in the third quarter on the plasma front.

    當然,當然。這裡有多重影響因素。首先,隨著我們進入第三季,我們確實預期在血漿業務方面,產能與市場供應將具備更高的彈性。如我們所提到的,我們目前已在生產,並預期在血漿方面能於第三季開始出貨。

  • And just the way tenders have worked out this year, if I step back and look at sales calendarization for 2013 for the Company, Q1 given some year-over-year comp issues around timing of tenders as well as this selling day issue, one last day in Q1, we'll have one more in Q3. Q2 and Q4 I would characterize as normal. And then in Q3 in particular, some significant emerging-market related tenders are scheduled this year versus prior year's being in different quarter, so we do expect to accelerate topline growth related to that as well.

    另外,就今年標案(tenders)的安排方式而言,如果我退一步看公司 2013 年的銷售在各季的分布,第一季因為一些與標案時點相關的年對年比較因素,以及營業天數的問題(第一季少一天,而第三季會多一天)。第二季與第四季我會形容為正常。而特別是在第三季,今年安排了一些與新興市場相關的重要標案,相較於前一年是在不同季度,因此我們也預期這將帶動營收成長加速。

  • The benefits of our business optimization efforts that we announced at the end of the fourth quarter this year, we'll start to see enhanced benefits from that as we move throughout the course of the year. So these are just some of the key drivers.

    至於我們在今年第四季末宣布的業務優化(business optimization)措施,其效益將在今年進程中逐步顯現並帶來更強的貢獻。以上只是一些關鍵的驅動因素。

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Okay.

    好的。

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • And Larry, I would just add, just so everybody knows, gross margin we do expect to be lower in the second half as we bring the Gambro business into the mix. So just so you have that, it will be lower than the first half.

    另外,Larry,我想補充一下,讓大家都知道,隨著我們把 Gambro 業務納入組合,我們確實預期下半年毛利率會較低。所以先讓你們掌握這點,它會低於上半年。

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Okay, thanks for that color, and then just two other quick ones. Can you just help us understand the implications of the warning letter on the Spectrum pump and how that folds into your guidance for this year?

    好的,謝謝補充說明,另外還有兩個很快的問題。你能否協助我們理解針對 Spectrum 幫浦的警告信之影響,以及這如何納入你們今年的財測指引?

  • And then separately on the Phase III Alzheimer's there, the first trial where you're expecting the topline results in the 2Q, is that actually tied to a scientific meeting? Or is that sort of a press release, as you finalize that data analysis?

    另外,關於阿茲海默症的第三期試驗,第一個你們預期在第二季公布主要結果(topline results)的試驗,那是否其實與某個科學會議綁定?還是說在你們完成資料分析後,會以新聞稿方式發布?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Let me -- I'll address the question on the warning letter, Mary Kay why don't you respond on the Alzheimer's question. So the warning letter that was communicated earlier this week really has to do with the clear status on some modifications that have been made to the SIGMA Spectrum pump over the year since the initial approval, the initial 5, 10-K a number of years ago. So the agency has requested additional information and documentation from us on those changes, that was largely the basis of the warning letter.

    我先來——我會回答警告信的問題;Mary Kay,阿茲海默症的問題你來回應好嗎。本週稍早所傳達的那封警告信,主要是關於 SIGMA Spectrum 幫浦在最初核准後、以及多年前最初的 5、10-K 之後這一年間所做的一些修改,其合規狀態需要釐清。因此主管機關要求我們就這些變更提供額外資訊與文件,這大致就是警告信的主要依據。

  • The implications going forward is, in response to your question, Larry, yes there will be some impact on that on sales for the rest of the year, largely having to do with our focus, and actually per our discussions and agreement with the FDA, we're going to continue to support service and place devices in our existing accounts. The majority of our sales of SIGMA are into our existing account base. However, until we get these issues resolved, submit the data, get it reviewed, which we would hope to get completed this fall, and typically there would be about a 90-day review period, we are not going to place SIGMA devices in what I will call new accounts or competitive accounts. And so there is some sales and margin loss as a result of that action, obviously it didn't impact our overall sales guidance. So does that answer your question?

    至於後續影響,回應你的問題,Larry,是的,今年剩餘期間的銷售會受到一些影響,主要與我們的聚焦有關;而且依照我們與 FDA 的討論與協議,我們將持續在既有客戶中提供服務並部署設備。我們 SIGMA 的大多數銷售都來自既有客戶基礎。不過,在我們解決這些議題、提交資料並完成審查之前——我們希望能在今年秋季完成提交,而通常審查期約 90 天——我們不會在我所稱的「新客戶」或「競爭性客戶」中部署 SIGMA 設備。因此,這項措施會造成一些銷售與毛利的損失;但顯然它並未影響我們整體的銷售指引。這樣有回答到你的問題嗎?

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Yes, I take it you don't want to quantify how much you think you may lose?

    有,我理解你們不想量化你們認為可能會損失多少?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • I don't know.

    我不知道。

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • I think I can at least frame for you what our expectation was. So in our original 2013 guidance we assumed approximately $80 million in sales related to Spectrum in the US. And so obviously we have one quarter under our belt and sales were approximately $20 million. And then as Bob mentioned, a little bit more than 50% of our sales were targeted to go towards existing customers as well. So I think as you peel off the pieces here and you think about the last nine months of the year, how much sales we had in our original expectation and the fact that a fair amount of that was targeted towards existing customers, we think this is manageable within the context of the Med Products guidance, as well as the overall Company sales and EPS guidance.

    我想我至少可以幫你界定我們原本的預期。在我們最初的 2013 年指引中,我們假設美國市場與 Spectrum 相關的銷售約為 8,000 萬美元。顯然我們已經走過一個季度,銷售約為 2,000 萬美元。另外如 Bob 提到的,我們有略高於 50% 的銷售原本就鎖定既有客戶。所以當你把這些部分拆開來看,並思考今年剩下九個月我們原先預期的銷售額,以及其中相當一部分原本就面向既有客戶,我們認為在醫療產品(Med Products)指引,以及公司整體銷售與 EPS 指引的框架下,這是可控、可管理的。

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Okay, got it.

    好的,了解了。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Alzheimer's, go ahead.

    阿茲海默症的部分,請說。

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Larry, that data on Alzheimer's. So as we mentioned, we did lock the database recently, and we're in the process of analyzing the data. So we do expect to issue a press release during the second quarter with the topline results. I think as we mentioned last quarter, we do plan to have the full data set available at an upcoming medical conference, which is in July.

    Larry,關於阿茲海默症的資料。如我們提到的,我們最近已完成資料庫鎖定(lock the database),目前正在分析資料。因此我們確實預期會在第二季以新聞稿發布主要結果(topline results)。我想如我們上季提到的,我們計畫在即將到來、7 月的醫學會議上提供完整資料集。

  • Larry Keusch - Analyst

    Larry Keusch - Analyst

  • Okay, terrific. Thanks very much, guys.

    好的,太好了。非常感謝,各位。

  • Operator

    Operator

  • Mike Weinstein, JPMorgan.

    下一位是 JPMorgan 的 Mike Weinstein。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Thank you, good morning. So a couple cleanup questions here. The issue you cited in the biopharma solutions, the partnering business this quarter, that sounds like it's been resolved. Will there be a catch-up in the second quarter since the business that you lost this quarter you get in the second quarter?

    謝謝,早安。我這裡有幾個釐清問題。你們提到本季生物製藥解決方案(biopharma solutions)中的合作夥伴業務(partnering business)出現的問題,聽起來已經解決了。那第二季會不會有追補(catch-up),因為你們本季流失的業務會在第二季回來?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • It won't all be in the second quarter, but most of it will be caught up, Mike, in the remainder of the year.

    不會全部都在第二季,但其中大部分會在今年剩餘期間補回來,Mike。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Okay. Thank you. On HyQvia, the preclinical work that you were doing for the FDA, could you update us on where you are? Have you done the interim analysis of that, and can you give us some insights into when that will be presented to the agency?

    好的。謝謝。關於 HyQvia,你們為 FDA 進行的臨床前(preclinical)工作,可以更新一下進度嗎?你們是否已做了期中分析(interim analysis),以及能否分享何時會向主管機關提交/呈報?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Yes, Mike. We have the interim data and we do plan on meeting with the FDA in the second quarter as we had articulated at the last conference call.

    是的,Mike。我們已取得期中資料,並且如同我們在上次電話會議所說明的,我們計畫在第二季與 FDA 會面。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Okay. And is that anything that we will see, that data?

    好的。那我們會看到那些資料嗎?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • No.

    不會。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Okay.

    好的。

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • But we will be able to give you an update probably at the second quarter call on where we are with HyQvia after the meeting with the FDA.

    不過,在與 FDA 會面之後,我們大概可以在第二季電話會議時,向你們更新 HyQvia 的進展狀況。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Okay, and just one more. And the process here with Gambro, have you been able to gain any additional insights into their business, anything that might change your views on integration or on the opportunity for the acquisition, either short or longer term?

    好的,最後再一個。關於 Gambro 的流程,你們是否對他們的業務有任何新的洞見?有沒有任何事情會改變你們對整合或併購機會的看法,不論是短期或長期?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • No. No major changes.

    沒有。沒有重大變化。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Okay and lastly, just on the performance of the renal side of the business this quarter, you cited some austerity measures in China. Can you maybe just call out what those were and anything else that --

    好的,最後,關於本季腎臟業務(renal side)的表現,你們提到中國的一些緊縮措施(austerity measures)。你能否具體說明那些是什麼,以及還有其他任何——

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • They were largely price reductions, Bob, why don't you --

    主要是降價,Bob,你要不要——

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • We've characterize austerity overall as impacting top line and margin frankly by approximately $90 million for the full year. China is about one-third of that, not all of it related to the renal business, but a good chunk of it is related to the renal business. This is something that's been discussed for the last several years, and they finally implemented a rebasing of the reimbursement level there. And so we continue to have strong growth from a patient perspective, working very closely with the government in China, see great opportunities to continue to expand our footprint there, but we are encountering a price reduction here in 2013 that's going to impact growth rates.

    我們將整體緊縮(austerity)描述為對全年營收(top line)與毛利率的影響約 9,000 萬美元。中國約占其中三分之一,並非全部都與腎臟業務相關,但其中相當一部分確實與腎臟業務有關。這件事過去幾年一直在討論,他們終於在當地實施了給付水準(reimbursement level)的重新基準化(rebasing)。因此,從病患角度來看我們仍持續強勁成長,並與中國政府密切合作,也看到很好的機會能持續擴大我們在當地的布局,但我們在 2013 年面臨降價,將影響成長率。

  • Mike Weinstein - Analyst

    Mike Weinstein - Analyst

  • Okay, perfect. That's all I have. Thanks, guys.

    好的,完美。我就這些。謝謝各位。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Matt Dodds, Citigroup.

    下一位是 Citigroup 的 Matt Dodds。

  • Matt Dodds - Analyst

    Matt Dodds - Analyst

  • Good morning. A couple quick questions. On Gambro, do you have an update on where the EU regulatory authorities are for Antitry?

    早安。兩個簡短問題。關於 Gambro,你們能否更新一下歐盟監管機關對 Antitry 的進度到哪裡了?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • No I don't think it's appropriate for us to comment at this point in time. We continue to work closely with them and that's all we can say at this point.

    不,我認為目前我們不適合對此發表評論。我們仍持續與他們密切合作,目前我們能說的就只有這些。

  • Matt Dodds - Analyst

    Matt Dodds - Analyst

  • Okay. And then for Albumin, up 2% with IG, is that also entirely due to constraints on the supply or is Albumin, is that more of the growth rate you're seeing?

    好的。那麼關於白蛋白(Albumin),在 IG 帶動下成長 2%,這也完全是因為供應受限所致嗎?還是白蛋白更反映你們目前看到的成長率?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • No, no. We're continuing to sell all the Albumin we can make, and so we do have some seasonality to availability of supply given normal year-end shut downs we do in most of our facilities and so on. We do expect strong Albumin growth throughout the course of the rest of the year. So, I think it's really just a Q1 phenomenon here.

    不,不是。我們持續把能生產的白蛋白全部賣出去;而且由於我們在多數設施於年底會有例行性的停工等因素,供應可得性確實存在一些季節性。我們預期在今年剩餘期間白蛋白將維持強勁成長。所以我認為這真的只是第一季的現象。

  • Matt Dodds - Analyst

    Matt Dodds - Analyst

  • Okay, so most of the tenders you commented on in Q1, that was plasma factor VIII?

    好的,所以你在第一季提到的大多數標案(tenders),是血漿來源的第八凝血因子(plasma factor VIII)?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Yes, that is correct, Matt.

    是的,沒錯,Matt。

  • Matt Dodds - Analyst

    Matt Dodds - Analyst

  • Great. Thanks, Bob, thanks Mary Kay.

    太好了。謝謝,Bob,謝謝 Mary Kay。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    Goldman Sachs 的 David Roman。

  • David Roman - Analyst

    David Roman - Analyst

  • Good morning everyone. I just wanted to follow up a little bit more on the IV IG and Albumin dynamics. Understandably there are some factors influencing your growth rate right now, but as we sort of look through the balance of the year, and beyond that, what do you think it's going to take for you to get back to growing at or above market rates? And I think most would say that IV IG is still growing at sort of high-single digit range, and Albumin, probably tracking surgical volumes globally, but what is the path to getting your business back toward kind of that sort of market growth rate in either of those franchises?

    各位早安。我想再追問一下 IV IG 與白蛋白的動態。可以理解目前有一些因素正在影響你們的成長率,但當我們看今年剩餘期間以及更長期時,你認為要怎麼做才能回到以市場成長率或高於市場成長率的速度成長?我想多數人會說 IV IG 仍以高個位數成長,而白蛋白大概是跟全球手術量走勢一致;但在這兩個產品線中,你們要如何讓業務回到接近市場成長率的路徑是什麼?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • More capacity. Go ahead, Bob.

    更多產能。Bob,你來說。

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • I think this really is -- we continue to see very strong demand for our product. As you know because of the constraints we've had, we've had to be very selective about which markets outside the US we even participate in as an example. And so we do continue to see strong demand for IGs globally, and so we expect as we bring meaningful capacity online here, and get Old LA back into a mode where we can sell the product commercially, that we're going to be able to participate at least at market growth rates going forward.

    我認為這其實是——我們仍然看到對我們產品非常強勁的需求。如你所知,由於我們面臨的產能限制,我們不得不非常有選擇性地決定甚至連美國以外哪些市場要參與,舉例來說就是如此。因此我們確實持續看到全球對 IG 的強勁需求;我們預期當我們在這裡把具規模的產能上線,並讓 Old LA 回到可以商業化銷售產品的狀態時,未來我們至少能以市場成長率的速度參與競爭。

  • And as it relates to Albumin, while I would say your characterization around in most countries this tracking with surgical volumes and so on is probably pretty good with the exception of China, which I think continues to be in a situation where because of decisions they've taken locally about shutting down collection and so on, they're going to continue to import a significant amount of Albumin going forward, and that's one I think that offers an opportunity for us to continue to grow as we have more capacity come online.

    至於白蛋白,我會說你提到在多數國家其走勢與手術量等因素連動,這個描述大致正確;但中國是個例外。我認為中國因為當地做出關閉採集等決策,未來仍將持續進口大量白蛋白;而這一點在我們有更多產能上線後,會提供我們持續成長的機會。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • And that looks to be a long-term opportunity there.

    而那看起來會是一個長期機會。

  • David Roman - Analyst

    David Roman - Analyst

  • And then in some of the decisions that you've taken in Europe, obviously makes sense given the capacity constraints and the relative pricing environment, but do you think that has any impact on your ability to launch HyQvia there and gain traction? Is there something that has to have a tender perspective for you to get that product to the market, or is there enough of sort of high-end segment of the market that would be able to adopt it at reasonable ASPs pretty quickly?

    另外,關於你們在歐洲所做的一些決策,考量到產能限制與相對的定價環境,顯然是合理的;但你認為這會不會影響你們在那裡推出 HyQvia 並取得進展的能力?你們是否需要從標案(tender)的角度才能把該產品推向市場?還是市場中有足夠的高端區隔,能夠在合理的平均售價(ASP)下很快採用?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Yes, I think a couple of factors. Number one, we are very excited about the opportunity both in Europe and the US for HiQ; we think this is a significant improvement for patients from a convenience standpoint while offering all of the safety and efficacy that we see in our base product. And so the long term we think HiQ is a great opportunity, but as we hopefully get approval here and can launch in the back half of 2013 in Europe, it's going to be a controlled launch. We have the issue of capacity to consider here as well. But we are still in a number of important markets in Western Europe as an example. So I think there's plenty of opportunity within the markets we're a major participant in today to initially launch HiQ.

    是的,我想有幾個因素。第一,我們對 HiQ 在歐洲與美國的機會都非常興奮;我們認為從便利性角度來看,這對病患是顯著的改善,同時也提供我們基礎產品所具備的所有安全性與療效。因此長期而言,我們認為 HiQ 是很好的機會;但如果我們如期在這裡獲得核准,並能在 2013 年下半年於歐洲上市,將會採取受控式上市。我們也必須把產能問題納入考量。不過以西歐為例,我們仍在多個重要市場中。所以我認為在我們目前已是主要參與者的市場裡,有足夠的機會可以先行推出 HiQ。

  • We are going to launch at a premium because we do think the product, given its characteristics and convenience that it offers, is worthy of a meaningful premium. And so again what we're going to do a control launch, ensure patients and treaters are aware of the process for the enhanced therapy, and that it gets off to a very good start, because we do want to make sure this is successful over the long term. In the near term I don't see this being an issue in terms of market participation in Europe because the key markets we would likely launch HiQ in anyway we're already in still with IGs.

    我們會以溢價推出,因為我們確實認為該產品基於其特性與所提供的便利性,值得有相當幅度的溢價。因此我們會採取受控式上市,確保病患與治療端了解這項加強療法的流程,並讓上市有一個非常好的開始,因為我們希望確保長期成功。短期內我不認為這會在歐洲的市場參與上造成問題,因為我們可能會推出 HiQ 的關鍵市場,本來就仍有 IG 產品在那裡。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay. Maybe just one financial question. As I look at the SG&A number, this quarter as a percentage of revenue, I think that's the highest it's been in quite some time, and you did cite some promotional activities and investments that you are making. But how should we think about the opportunity for leverage on discretionary line items going forward, are you entering more of an investment period to drive topline growth in areas like emerging markets? Or is there something that's more one-off in the first quarter whereby that line item should start to look a little bit more like it has in the past going forward?

    好的。也許再問一個財務問題。我看本季的 SG&A 數字占營收比重,我想這是相當長一段時間以來最高的,你也提到了一些推廣活動與投資。但往後我們應該如何看待在可裁量費用項目上的槓桿空間?你們是否正進入一個投資期,以推動新興市場等領域的營收成長?或者第一季是否有較一次性的因素,使得該項目往後應該會更接近過去的水準?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Yes. I think a couple dynamics. For the full year for sure as I mentioned in my prepared comments, we expect in the base Baxter expense base we're going to drive leverage relative to sales for the full year. Q1 had some interesting dynamics, obviously given the issues in our pharma partnering business we came in a little bit lower on the top line in the quarter. As it relates to things like pension expense, that accounted for about 1.5% of growth in the quarter, given that impact for the full year.

    是的。我想有幾個動態。就全年而言,正如我在事先準備的評論中提到的,我們預期在 Baxter 的基礎費用結構上,全年會相對於銷售實現費用槓桿。第一季有一些有趣的動態,顯然因為我們製藥合作夥伴業務的問題,本季營收端略低。至於像退休金費用這類項目,在本季約占成長的 1.5%,而這個影響會延續到全年。

  • As I mentioned, our business optimization efforts will provide increasing benefits as we move throughout the course of the year. We have been and will continue to make the right investments to ensure we can enhance our position in emerging and developing markets, so no change there. We do have some additional spending in advance of the key product launches like we've discussed today around HiQ, and also home HD, which we've made good progress on the trials. Bob mentioned in his comments, and look for CE Mark here in Europe. So I think it's a balance of targeted investment for the growth opportunities we have and leveraging our existing base through process reengineering.

    如我所提,我們的業務優化工作將在今年進程中帶來愈來愈多的效益。我們一直在、也將持續做出正確的投資,以確保能強化我們在新興與開發中國家市場的地位,這點沒有改變。在一些關鍵產品上市之前,我們也有額外支出,例如今天討論的 HiQ,以及居家 HD(home HD),我們在試驗上已取得良好進展。Bob 在他的評論中也提到,並且我們在歐洲這裡正期待取得 CE Mark。所以我認為這是在針對我們的成長機會進行有目標的投資,以及透過流程再造來槓桿化既有基礎之間取得平衡。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay. That's helpful, thank you.

    好的。很有幫助,謝謝。

  • Operator

    Operator

  • Kristen Stewart, Deutsche Bank.

    Deutsche Bank 的 Kristen Stewart。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Thanks. I just wanted to clarify. In the other income line that you had said that that did include $10 million of a gain related to sell of an intangibles, any color on that?

    謝謝。我只是想釐清一下。在你提到的其他收入(other income)項目中,你說其中包含與出售某項無形資產相關的 1,000 萬美元收益;能否補充一些背景說明?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • No, it's an arrangement we had in a country, so I don't think it's something we want to get into a lot of detail around. It is a one-off, but as I mentioned the other driver there was FX and other income, it's not something we planned or expect to incur again.

    不,這是我們在某個國家的一項安排,所以我不認為這是我們想要深入談很多細節的事情。這是一次性的,但如我提到的,另一個驅動因素是外匯與其他收入;這不是我們規劃過或預期會再次發生的項目。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Okay, got you. And then just kind of working through the gross margin, sounds like that was more moderated. Is that simply all foreign currency or is that any other thing impacting your expectations on the gross margin line?

    好的,了解。接著談毛利率,看起來那部分比較溫和。那純粹都是外幣因素嗎?還是有其他事情影響你們對毛利率項目的預期?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • It definitely is currency related.

    確實是與匯率相關。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Okay. Any update on the recombinant von Willebrand product in terms of the trial or expected launch for approval for filing?

    好的。關於重組 von Willebrand 產品,在試驗進度或預期上市、以及申請核准/送件方面,有沒有最新進展?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Yes, Kristen, I think we had mentioned that we have completed enrollment in the end of the fourth quarter and we actually have now completed the dosing of the last patient.

    有的,Kristen,我想我們先前提過,我們已在第四季末完成收案,而現在也已完成最後一位病患的給藥。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Okay, and when might you be in the position to I guess file with the FDA on that?

    好的,那你們大概什麼時候能夠向 FDA 送件申請呢?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Well, there's a 12 month follow-up, so we will complete the trial probably beginning of next year and file next year.

    嗯,因為需要 12 個月的追蹤,所以我們大概會在明年年初完成試驗,並在明年送件。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Okay. All right. And then just lastly Mary Kay, I think you had mentioned on ADVATE that you're planning on taking down inventory for the balance of the year; can you maybe just explain why that is?

    好的。好。最後一個問題,Mary Kay,我想你提到 ADVATE 今年剩餘期間你們計畫降低庫存;可以說明一下原因嗎?

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • Yes, Kristen, I think we talked about the course of a few quarters last year, there has been some shakeout in the US amongst the SPPs from a market share standpoint, and as a result, one of our key customers has gotten into a situation where they've lost some share and we were working with them to rightsized their inventory level given that new share situation. And so I think over the next several quarters we're talking in the range of approximately $15 million that we will be working off from a US recombinant standpoint.

    好的,Kristen,我想我們去年談過幾個季度,美國的 SPP(專科藥局供應商)在市占率方面出現了一些洗牌;因此,我們的一位主要客戶因為流失了一些市占而處於一種狀況,我們正與他們合作,依照新的市占情況把庫存水位調整到合理規模。所以我想在接下來幾個季度,我們談的是大約 1,500 萬美元的量,將從美國重組產品的角度逐步消化掉。

  • Kristen Stewart - Analyst

    Kristen Stewart - Analyst

  • Okay, that's helpful. Thank you very much.

    好的,這很有幫助。非常感謝。

  • Operator

    Operator

  • Bob Hopkins, Bank of America.

    美國銀行的 Bob Hopkins。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Great. Good morning. Just a couple quick things. First, just given the visibility of the Alzheimer's program, I was wondering if you could give us a little more of a direct sense on timing within the second quarter, should we expect that more first-half disclosure or second-half disclosure? And have you, just give us a little update on exactly what you will be presenting within those headline results in the press release? Thanks.

    很好。早安。我有幾個簡短問題。首先,鑑於阿茲海默症計畫的能見度,我想請你們更直接地談談第二季內的時間點:我們應該預期比較偏上半季揭露,還是下半季揭露?另外,也請更新一下,你們在新聞稿中針對這些重點結果,究竟會呈現哪些內容?謝謝。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • Go ahead, Mary Kay --

    Mary Kay,你先說——

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • We can't be more specific. As we mentioned we locked the database and we're working diligently with our partner on this, ADCS, and so we're certainly as motivated as everyone to get the results compiled and be able to release those. As we mentioned earlier it will be in the form initially of a press release for the topline results of the two primary endpoints, and some subgroup analysis related to mild versus moderate and ApoE4 versus non-ApoE4. Those of the stratifications that we will be able to provide initially, and as Mary Kay mentioned have the full data set at a conference likely in July.

    我們無法更具體。如同我們提到的,我們已鎖定資料庫,並正與合作夥伴 ADCS 勤奮地推進,因此我們當然和大家一樣迫切希望把結果彙整完成並對外發布。如先前所述,初步會以新聞稿形式發布兩個主要終點的頂線結果,以及一些子群分析,包含輕度對中度、以及 ApoE4 對非 ApoE4。這些是我們一開始能提供的分層資訊;另外,如 Mary Kay 提到的,完整資料集可能會在七月的某個會議上公布。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Alright. Great, thank you. And the other question I have was just I was wondering if you could give us an update on the 855 program just in terms of milestones and timelines that we should expect for the rest of this year and going forward, given that obviously that's a pretty important program from a competitive perspective? Thanks.

    好的。非常好,謝謝。我另一個問題是,想請你們更新一下 855 計畫的進度,就今年剩餘時間以及往後我們應該期待的里程碑與時程;顯然從競爭角度來看,這是一個相當重要的計畫。謝謝。

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Thanks, Bob. BAX855, we started the Phase III trial and we began dosing patients during the first quarter; this trial includes over 100 patients and we expect to complete enrollment by the end of this year. And we are remaining on track to file sometime next year.

    謝謝你,Bob。BAX855 我們已啟動第三期試驗,並在第一季開始對病患給藥;此試驗包含超過 100 位病患,我們預期在今年底前完成收案。我們也仍按計畫在明年某個時間點送件申請。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Alright, great. And then just last pipeline question for me. I realize this is a bit of a softball question, but can you just give me a sense of the best case scenario on HiQ in the US? Things go as well as you hoped they could possibly go, what would that mean from a timing perspective? Thanks.

    好的,很好。最後一個產品線問題。我知道這有點像是送分題,但你能不能讓我了解一下 HiQ 在美國的最佳情境?如果一切都如你們所希望、甚至是最順利的狀況,從時程角度會代表什麼?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • I don't think we're going to speculate on that. Obviously we have our meeting with the FDA which we described, we're encouraged by the progress we've made in Europe, hopefully that will be helpful with our discussions here in the US, but I think, Bob, to speculate beyond that we don't want to do that. So --

    我想我們不會對此做推測。顯然我們會如所描述與 FDA 開會;我們對在歐洲取得的進展感到鼓舞,希望這能對我們在美國的討論有所幫助,但我想,Bob,要再往下推測我們不想這麼做。所以——

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Bob, just recall, though that we aren't going to complete the preclinical trials until the end of this year. So obviously we'll have more information once we meet with the FDA on the interim results.

    Bob,不過請記得,我們要到今年底才會完成臨床前試驗。所以等我們與 FDA 就期中結果會面後,顯然會有更多資訊。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Glenn Navarro, RBC Capital Markets.

    RBC 資本市場的 Glenn Navarro。

  • Glenn Novarro - Analyst

    Glenn Novarro - Analyst

  • Hi, good morning. I'm curious, Bob, if you can give us your interpretation of what's occurring in the US with respect to utilization? We've seen hospitals now preannounce disappointing results, some lab companies as well. Do you think, we're seeing heightened seasonality in the fourth quarter, and that's pulling sales from the first quarter, just any color you can provide?

    嗨,早安。我想請教一下,Bob,你能否分享你對美國端使用量(utilization)現況的解讀?我們看到一些醫院預先公告令人失望的結果,一些檢驗公司也是。你認為我們是否看到第四季季節性更強,導致把第一季的銷售提前拉走?你能提供任何補充說明嗎?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • I think the markets is soft, it's going to continue to remain soft, I think is our view. I think as it relates to our products given the nature -- the medically necessary nature of our products, the impact will be modest, but I think to suggest that you are going to see a turnaround, Glenn, from the softness we've seen over the last quarter or so, would probably be a little too optimistic. I just think the market conditions are going to continue to be very challenging.

    我認為市場偏疲弱,而且依我們的看法,這種疲弱會持續。就我們的產品而言,考量到我們產品的性質——屬於醫療必需品——影響會相對有限;但如果要說你會看到從過去一季左右的疲弱中出現反轉,Glenn,那可能就有點過度樂觀了。我只是認為市場環境將持續非常具挑戰性。

  • Glenn Novarro - Analyst

    Glenn Novarro - Analyst

  • Okay. And just a follow up, a lot of investors ask me about 2014 with respect to healthcare reform, should we anticipate a volume bump? What are your thoughts on that?

    好的。再追問一下,很多投資人會問我 2014 年在醫療改革方面的影響;我們是否應該預期量會增加?你們怎麼看?

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • I wouldn't -- I don't anticipate to see any meaningful incremental impact on our business due to evolving healthcare reform implementation and so on. So whether it's 2014, Glenn, or out over the long-range plan, frankly, our views going forward haven't changed from our investor conference last fall on this.

    我不會——我不預期醫療改革的推動與落實等,會對我們的業務帶來任何有意義的額外增量影響。所以不論是 2014 年,Glenn,或是更長期的規劃期,坦白說,我們對未來的看法與去年秋天投資人會議時所說的並沒有改變。

  • So look, we all know what the general dynamics are globally, even outside the US, which is a difficult economic environment; healthcare costs continue to rise at a rate that is beyond any government's ability to control, and there are going to continue to be impacts that we characterize as quote-unquote, austerity measures on healthcare spending that I think our going to continue to impact all multi-national companies, whether it's in the US or outside the US. But again, and I would not suggest that we're impervious to those kinds of impacts, but they will be evolutionary in nature, they're not going to be major step function impacts.

    你看,我們都知道全球的一般動態,即便在美國以外也是如此:經濟環境艱困;醫療成本持續以超出任何政府可控範圍的速度上升;而我認為,醫療支出上將持續出現我們所稱的「所謂的」緊縮措施(austerity measures),並將持續影響所有跨國公司,不論是在美國或美國以外。但再說一次,我不會說我們對這類影響完全免疫;只是它們會是漸進式的,不會是那種重大的階躍式衝擊。

  • And again, as I said earlier I'd emphasize given the medically necessary nature of our products, we think we're going to be able to withstand this certainly reasonably well and where the focus really is, as it always has been in this industry, is innovation. And with our emerging pipeline, not to mention the expanding capacity position over time on plasma proteins and continued robust demand for those products, that's where our focus is and we certainly can, I think withstand the general macro dynamics that we discussed.

    再一次,如同我先前所說,我要強調,鑑於我們產品在醫療上屬於必要性質,我們認為我們將能夠承受這些影響,當然整體而言會相當穩健;而真正的重點,如同這個產業一向如此,在於創新。再加上我們正在成形的研發管線,更不用說隨時間推進在血漿蛋白產能上的擴充布局,以及對這些產品持續強勁的需求,這些才是我們的聚焦所在;我認為我們確實能夠承受我們所討論的一般宏觀動態。

  • Glenn Novarro - Analyst

    Glenn Novarro - Analyst

  • Okay, great. Thanks for the color, Bob.

    好的,很棒。謝謝你提供的補充說明,Bob。

  • Operator

    Operator

  • Rick Wise, Stifel Nicolaus.

    Rick Wise,Stifel Nicolaus。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Good morning, everybody. Hi, Bob. If I could ask a little more color on the home hemo program. It seems to be clearly on track as you've suggested in the past. Maybe just remind us again when the trial wraps up what the filing and approval timing process is. And I keep thinking that just given the current market dynamics that this is a more promising program than ever. Any thoughts again about the potential penetration or the opportunity here?

    各位早安。嗨,Bob。如果可以的話,我想再多問一些關於居家血液透析(home hemo)計畫的細節。看起來如同你過去所提到的,這個計畫顯然進展順利、按部就班。也許請你再提醒我們一次,試驗結束後,申報與核准的時程流程是怎麼走的。而且我一直在想,考量目前的市場動態,這個計畫似乎比以往任何時候都更具前景。你是否能再談談潛在滲透率或這裡的機會?

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • I will take the first half of the question, Rick, and then Bob can take the market opportunity part of your question. But in terms of the trial, the Canadian trial is going to be wrapping up here in the second quarter, and then we will be wrapping up the submission and we expect to CE Marking by the end of this year. As you recall in the US, we're still in discussions with the FDA as to whether or not they will require one or two trials here in the US, but we're still planning for a nocturnal indication, filing in 2014.

    Rick,我先回答問題的前半段,然後Bob再回答你關於市場機會的部分。就試驗而言,加拿大的試驗將在第二季結束,之後我們會完成送件準備,並預期在今年底前取得CE認證(CE Marking)。如你所記得的,在美國方面,我們仍在與FDA討論他們是否會要求在美國進行一項或兩項試驗,但我們仍規劃以夜間適應症(nocturnal indication)在2014年提出申請。

  • Bob Parkinson - Chairman and CEO

    Bob Parkinson - Chairman and CEO

  • So Rick, Bob Parkinson here, maybe just to wrap up on kind of the higher-level question, we continue to be extremely enthusiastic about the opportunity associated with our home hemodialysis product, which we think has a number of dimensions or characteristics that can differentiate it from the home hemo products that are on the market today, not to mention to leverage our global position as really the leading dialysis provider in the home setting, which has real value here.

    Rick,我是Bob Parkinson。就你較高層次的問題做個收尾:我們對居家血液透析產品所帶來的機會仍然非常、非常有熱忱。我們認為它具備多個面向或特性,能夠與目前市面上的居家血透產品形成差異化;此外,也能運用我們在居家場景中作為全球領先透析服務提供者的地位,這在此確實具有很高的價值。

  • I think when you take a step back and look at this, this is the kind of product that is responsive to I think the new realities of the global economic environment on healthcare environment. The opportunity to enhance clinical outcomes we think meaningfully, particularly with home nocturnal hemo, to provide as a result increased convenience for the patient to deliver therapy in their home, and to do it in a way that fundamentally lowers the cost versus conventional in-center hemodialysis is really the kinds of products going forward that we think there's going to be a great response in the marketplace too.

    我認為退一步來看,這類產品能回應我所認為的全球經濟環境與醫療照護環境的新現實。我們相信,特別是居家夜間血透,能夠在臨床結果上帶來有意義的提升;同時也能讓病患在家中接受治療而更便利;並且以一種相較於傳統院內(透析中心)血液透析能夠從根本降低成本的方式來提供治療。這正是我們認為未來市場會有很大回應的產品類型。

  • The only caveat I would say is the nature of this requires a motivated patient that doesn't describe 100% of the patient population, so in no way do I want to suggest that traditional home in-center hemo is going to continue to be both a growth vehicle and the primary therapy to address end-stage renal disease, hence our excitement about the Gambro acquisition. But I appreciate your question because I think as we go forward, get this product launched in Europe and expand beyond that, this is a product opportunity that's very significant for the Company going forward.

    我唯一要補充的但書是:這類治療需要有動機的病患,而這並不涵蓋100%的病患族群,所以我絕不想暗示傳統的院內血透不會持續成為成長動能與治療末期腎臟病(end-stage renal disease)的主要療法,這也是我們對收購Gambro感到興奮的原因。不過我很感謝你的提問,因為我認為隨著我們在歐洲推出這項產品並進一步擴展到其他地區,這將是公司未來非常重大的產品機會。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Just last quick one on China, I want to make sure I understood what Bob Hombach, you were talking about in your Med Product comments, China austerity. I just want to make sure I understood what you were talking about. And I hope I didn't miss it, but did you talk about the timing of ADVATE reimbursement? I don't think you've gotten it yet. When are you expecting that, and when are you expecting that Chinese launch? Thank you.

    最後再快速問一題關於中國。我想確認我是否正確理解你在醫療產品(Med Product)評論中提到的中國緊縮(austerity),Bob Hombach。我只是想確認我理解你在說什麼。另外希望我沒有漏聽,但你有談到ADVATE給付(reimbursement)的時程嗎?我想你們應該還沒拿到。你們預期何時會取得?以及預期何時在中國上市?謝謝。

  • Bob Hombach - CFO

    Bob Hombach - CFO

  • No, my comments about reimbursement adjustment down relates specifically to the renal business. We have got -- the launch of ADVATE in China is going to be -- take a long time to play out. The treatment rates today in China for hemophiliacs are very low even on plasma derived. So we've got a long way to go to develop that market, but that's one that could be primed for some of our approaches here around public-private partnerships, but we're a long way from anything there.

    沒有,我關於給付下調的評論是特別針對腎臟業務。至於ADVATE在中國的上市,將會是——需要很長時間才能逐步展開。目前中國血友病患者的治療率非常低,即使是使用血漿來源(plasma derived)產品也是如此。因此我們還有很長的路要走來培育那個市場;不過那也可能是適合我們在公私協力(public-private partnerships)方面一些作法的市場,但距離真正落地還很遠。

  • Mary Kay Ladone - Corporate VP, IR

    Mary Kay Ladone - Corporate VP, IR

  • Yes, Rick, we are awaiting reimbursement approval. You may recall we did get approval for the product last year, but we can't launch until we have the reimbursement approved, which we expect in the second half of this year.

    是的,Rick,我們正在等待給付核准。你可能記得我們去年已取得產品核准,但在給付核准之前我們無法上市;我們預期在今年下半年取得給付核准。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Thank you very much.

    非常感謝。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.

    各位女士先生,Baxter International今日的電話會議到此結束。感謝各位參與。